Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

References

• Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479–489.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Seystahl K, Wick W, Weller M . Therapeutic options in recurrent glioblastoma-An update. Crit Rev Oncol Hematol. 2016;99:389–408.
   PubMed Web of Science ®Google Scholar
• Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. JCO. 2015;33(10):1197–1213. doi:10.1200/JCO.2014.55.9575.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA.. 2013;110(47):19059–19064.
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48(1):52–58. doi:10.1080/02841860802537924.
   PubMed Web of Science ®Google Scholar
• Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, et al. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. Acta Oncol. 2016;55(4):418–422. doi:10.3109/0284186X.2015.1114679.
   PubMed Web of Science ®Google Scholar
• Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011;104(3):639–646. doi:10.1007/s11060-011-0565-x.
   PubMed Web of Science ®Google Scholar
• Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012;51(6):797–804.
   PubMed Web of Science ®Google Scholar
• Wang N, Jain RK, Batchelor TT. New directions in anti-angiogenic therapy for glioblastoma. Neurotherapeutics. 2017;14(2):321–332.
   PubMed Web of Science ®Google Scholar
• Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ, Crocker IR, Shu H-KG. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer. 2015;121(9):1456–1462. doi:10.1002/cncr.29234.
   PubMed Web of Science ®Google Scholar
• Emile G, Chauvenet L, Tigaud JM, Chidiac J, Pujade Lauraine E, Alexandre J. A clinical experience of single agent bevacizumab in relapsing ovarian cancer. Gynecol Oncol. 2013;129(3):459–462. doi:10.1016/j.ygyno.2013.02.035.
   PubMed Web of Science ®Google Scholar
• Nakaya A, Kurata T, Yokoi T, Iwamoto S, Torii Y, Katashiba Y, Ogata M, et al. Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer. Cancer Med. 2016;5(7):1381–1387. doi:10.1002/cam4.701.
   PubMed Web of Science ®Google Scholar
• Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol. 2015;3(6):1295–1300. doi:10.3892/mco.2015.630.
   PubMedGoogle Scholar
• Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, et al. Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Mol Oncol. 2016;10(8):1160–1168.
   PubMed Web of Science ®Google Scholar
• Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47(13):1955–1961. doi:10.1016/j.ejca.2011.04.019.
   PubMed Web of Science ®Google Scholar
• McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik O-PR, Sabbisetti VS, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471–2479. doi:10.1158/1078-0432.CCR-14-2332.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci USA. 2013;110(46):18632–18637.
   PubMed Web of Science ®Google Scholar
• Martin P, Noonan S, Mullen MP, Scaife C, Tosetto M, Nolan B, et al. Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. BMC Cancer. 2014;14:887.
   PubMed Web of Science ®Google Scholar
• Menter AR, Carroll NM, Sakoda LC, Delate T, Hornbrook MC, Jain RK, et al. Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(2):189–197. doi:10.1016/j.cllc.2016.07.008.
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. JCO. 1990;8(7):1277–1280. doi:10.1200/JCO.1990.8.7.1277.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. JCO. 2010;28(11):1963–1972. doi:10.1200/JCO.2009.26.3541.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181. doi:10.1016/S1053-4296(03)00031-6.
   PubMed Web of Science ®Google Scholar
• Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 2012;4:303–313.
   PubMedGoogle Scholar
• Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7):22–25.
   PubMed Web of Science ®Google Scholar
• Methodology WCCfDS. ATC/DDD Index 2016 [Available from: http://www.whocc.no/atc_ddd_index/].
   Google Scholar
• Yang X, Kong AP, Luk AO, Ozaki R, Ko GT, Ma RC, et al. Validation of methods to control for immortal time bias in a pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes. J Epidemiol. 2014;24(4):267–273.
   PubMed Web of Science ®Google Scholar
• Wagner CC, Held U, Kofmehl R, Battegay E, Zimmerli L, Hofer S. Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis. Acta Oncol. 2014;53(4):572–575. doi:10.3109/0284186X.2013.852240.
   PubMed Web of Science ®Google Scholar
• Levin VA, Chan J, Datta M, Yee JL, Jain RK. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. J Neurooncol. 2017;134(2):325–330.
   PubMed Web of Science ®Google Scholar
• Weberpals J, Jansen L, van Herk-Sukel MPP, Kuiper JG, Aarts MJ, Vissers PAJ, Brenner H. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis. Eur J Epidemiol. 2017;32(11):1019–1031. doi:10.1007/s10654-017-0304-5.
   PubMed Web of Science ®Google Scholar
• Carpentier AF, Ferrari D, Bailon O, Ursu R, Banissi C, Dubessy A-L, et al. Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol. 2012;19(10):1337–1342. doi:10.1111/j.1468-1331.2012.03766.x.
   PubMed Web of Science ®Google Scholar
• Kourilsky A, Bertrand G, Ursu R, Doridam J, Barlog C, Faillot T, et al. Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients. J Neurol. 2016;263(3):524–530.
   PubMed Web of Science ®Google Scholar
• Januel E, Ursu R, Alkhafaji A, Marantidou A, Doridam J, Belin C, et al. Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma. Eur J Neurol. 2015;22(9):1304–1309.
   PubMed Web of Science ®Google Scholar
• Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675–681. doi:10.1161/HYPERTENSIONAHA.109.149690.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;42516.
   PubMed Web of Science ®Google Scholar
• Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbaek M, Toft A, et al. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer. 2017;17(1):278.
   PubMedGoogle Scholar
• Emblem KE, Gerstner ER, Sorensen G, Rosen BR, Wen PY, Batchelor TT, Jain RK. Abstract 3975: matrix-depleting anti-hypertensives decompress tumor blood vessels and improve perfusion in patients with glioblastomas receiving anti-angiogenic therapy. Cancer Res. 2016;76(14):3975. doi:10.1158/1538-7445.AM2016-3975.
   Google Scholar
• Rizzoni D, De Ciuceis C, Salvetti M, Paini A, Rossini C, Agabiti-Rosei C, Muiesan ML. Interactions between macro- and micro-circulation: are they relevant? High Blood Press Cardiovasc Prev. 2015;22(2):119–128. doi:10.1007/s40292-015-0086-3.
   PubMed Web of Science ®Google Scholar